M&A analysis: Merck and Gilead splash the cash
The groups spend big on Terns and Arcellx.
Servier makes a rare big buy
The company pays $2.5bn for Day One and its approved drug Ojemda.
M&A analysis: bolt-ons for J&J and Bristol
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
Chimerix's cancer transformation
US approval could mark the company's graduation to oncology.
Biocytogen and PTK7 remain hot
First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.
FDA green and red lights: April 2024
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
